Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å undersøke Ronde-Cel versus Investigator's Choice CD19 CAR T-cellebehandling (PiNACLE-H2H)

2. november 2026 oppdatert av: Lyell Immunopharma, Inc.

En fase 3-randomisert kontrollert studie av Rondecabtagene Autoleucel, en autolog, dual-målrettet CD19/CD20 CAR T-celleproduktkandidat, kontra etterforskers valg av CD19 CAR T-cellebehandling hos pasienter med tilbakefall eller ildfast stor B-celle-lymfom i den andre linjen med pasienter med tilbakefall eller ildfast

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

Studieoversikt

Detaljert beskrivelse

PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.

Patients will be randomized (1:1) before leukapheresis to receive either:

  • Ronde-cel; or
  • Investigator's choice of axi-cel or liso-cel

Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.

Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.

Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.

Studietype

Intervensjonell

Registrering (Antatt)

400

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Queensland
      • Douglas, Queensland, Australia, 4814
        • Rekruttering
        • Townsville University Hospital
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Rekruttering
        • The Alfred
    • Ontario
      • Toronto, Ontario, Canada, M5G 2C4
        • Rekruttering
        • Princess Margaret Cancer Centre
    • Arizona
      • Gilbert, Arizona, Forente stater, 85234
        • Rekruttering
        • Banner MD Anderson Cancer Center
      • Scottsdale, Arizona, Forente stater, 85258
        • Rekruttering
        • Honor Health
      • Scottsdale, Arizona, Forente stater, 85259
        • Rekruttering
        • Mayo Clinic Arizona
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205
        • Har ikke rekruttert ennå
        • University of Arkansas
    • California
      • Los Angeles, California, Forente stater, 90048
        • Rekruttering
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • University of California, Los Angeles (UCLA)
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • University of California, Irvine
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • University of Colorado
      • Denver, Colorado, Forente stater, 80218
        • Rekruttering
        • Colorado Blood Cancer Institute
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20007
        • Rekruttering
        • MedStar Georgetown University Hospital
    • Florida
      • Jacksonville, Florida, Forente stater, 32224
        • Rekruttering
        • Mayo Clinic Florida
      • Orlando, Florida, Forente stater, 32804
        • Rekruttering
        • AdventHealth
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, Forente stater, 30342
        • Rekruttering
        • Northside Hospital
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Northwestern
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • Rekruttering
        • University of Iowa
    • Kansas
      • Westwood, Kansas, Forente stater, 66205
        • Rekruttering
        • University of Kansas Cancer Center
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • University of Louisville Health
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02111
        • Rekruttering
        • Tufts Medical Center
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68105
        • Rekruttering
        • University of Nebraska Medical Center (UNMC)
    • New Jersey
      • Hackensack, New Jersey, Forente stater, 07601
        • Rekruttering
        • Hackensack
      • Morristown, New Jersey, Forente stater, 07960
        • Rekruttering
        • Atlantic Health
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87102
        • Rekruttering
        • University of New Mexico Comprehensive Cancer Center
    • New York
      • Buffalo, New York, Forente stater, 14263
        • Rekruttering
        • Roswell Park Comprehensive Cancer Center
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Rekruttering
        • Duke Cancer Institute
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Har ikke rekruttert ennå
        • Atrium Health Wake Forest Baptist Comprehensive Cancer Center
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45267
        • Rekruttering
        • University of Cincinnati
      • Cincinnati, Ohio, Forente stater, 45242
        • Rekruttering
        • Oncology Hematology Care Clinical Trials
      • Cleveland, Ohio, Forente stater, 44195
        • Rekruttering
        • Cleveland Clinical Taussig Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15212
        • Har ikke rekruttert ennå
        • Allegheny Health Network
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, Forente stater, 78704
        • Rekruttering
        • St. David's South Austin Medical Center
      • Fort Worth, Texas, Forente stater, 76104
        • Rekruttering
        • University of Texas Southwestern Medical Center
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • MD Anderson Cancer Center
      • San Antonio, Texas, Forente stater, 78229
        • Rekruttering
        • Texas Transplant Institute
    • Utah
      • Salt Lake City, Utah, Forente stater, 84143
        • Rekruttering
        • Intermountain Healthcare
    • Virginia
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • Virginia Oncology Associates
      • Richmond, Virginia, Forente stater, 23298
        • Rekruttering
        • Virginia Commonwealth University-Massey Cancer Center
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Medical College of Wisconsin

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  1. CAR T cell naïve and eligible to receive a CD19 CART-cell therapy

  2. Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)

    • Diffuse large B-cell lymphoma (DLBCL)
    • Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
    • DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
    • High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
    • Primary mediastinal large B-cell lymphoma (PMBCL)
    • Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
  3. Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy

  4. Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria

  5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

  6. Adequate hematological, renal, hepatic, pulmonary, and cardiac function

Key Exclusion Criteria:

  1. Patients ineligible to receive CD19 CAR T-cell therapy
  2. Primary CNS lymphoma
  3. Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
  4. Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
  5. Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
  6. Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Rondecabtagene Autoleucel

An autologous, dual-targeting CD19/20 CAR T-cell candidate.

Andre navn:
  • LYL314
Aktiv komparator: Investigator's Choice CD19

axicabtagene ciloleucel, lisocabtagene maraleucel

An autologous CD19 CAR T-cell therapy

Andre navn:
  • Yescarta
  • akse-cel

An autologous CD19 CAR T-cell therapy

Andre navn:
  • Breyanzi
  • liso-cel

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Event free survival
Tidsramme: 36 months

The time interval from treatment initiation until the occurrence of a specific event of interest.

36 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Response Rate
Tidsramme: 36 months

Best Overall Response per Lugano Criteria

36 months
Complete Response Rate
Tidsramme: 36 months

Complete Response per Lugano Criteria

36 months
Progression Free Survial
Tidsramme: 36 months

The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.

36 months
Overall Survival
Tidsramme: 6 years

The length of time from either the date of diagnosis or the start of treatment for a disease, that patients diagnosed with the disease, are still alive.

6 years
Incidence and severity adverse events
Tidsramme: 36 months

To assess safety defined as type and frequency of AEs, serious adverse events (SAEs), and laboratory abnormalities.

36 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. januar 2026

Primær fullføring (Antatt)

1. desember 2029

Studiet fullført (Antatt)

1. januar 2032

Datoer for studieregistrering

Først innsendt

16. september 2025

Først innsendt som oppfylte QC-kriteriene

16. september 2025

Først lagt ut (Faktiske)

23. september 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere